{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:14:22Z","timestamp":1789409662428,"version":"build-2803163510"},"reference-count":129,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-178120"],"award-info":[{"award-number":["PJT-178120"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-136898"],"award-info":[{"award-number":["MOP-136898"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PYY-175428"],"award-info":[{"award-number":["PYY-175428"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["NHG-107767"],"award-info":[{"award-number":["NHG-107767"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007721","name":"Cure SMA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013873","name":"Government of Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omta.2026.201757","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:53:40Z","timestamp":1778770420000},"page":"201757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Extracellular vesicles as biomarkers of disease progression and therapeutic response in patients with spinal muscular atrophy"],"prefix":"10.1016","volume":"34","author":[{"given":"Kathy L.","family":"Poulin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte A.","family":"Ren\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis O.","family":"Vacratsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh J.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kothary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore J.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Warman-Chardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4959-2233","authenticated-orcid":false,"given":"Robin J.","family":"Parks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201757_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201757_bib2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamapediatrics.2024.1911","article-title":"Newborn Screening and Birth Prevalence for Spinal Muscular Atrophy in the US","volume":"178","author":"Belter","year":"2024","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.omta.2026.201757_bib3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2174\/1566524016666161128113338","article-title":"Spinal Muscular Atrophy: More than a Disease of Motor Neurons?","volume":"16","author":"Nash","year":"2016","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.omta.2026.201757_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","article-title":"Overturning the Paradigm of Spinal Muscular Atrophy as Just a Motor Neuron Disease","volume":"109","author":"Yeo","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omta.2026.201757_bib6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","article-title":"The survival motor neuron protein in spinal muscular atrophy","volume":"6","author":"Coovert","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2026.201757_bib7","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ana.410430513","article-title":"Association between centromeric deletions of the SMN gene and sporadic adult-onset lower motor neuron disease","volume":"43","author":"Moulard","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib8","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2026.201757_bib9","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201757_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/hmg\/9.2.259","article-title":"An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN","volume":"9","author":"Lorson","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2026.201757_bib11","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/hmg\/dds474","article-title":"A novel function for the survival motoneuron protein as a translational regulator","volume":"22","author":"Sanchez","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2026.201757_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nature16469","article-title":"SMN and symmetric arginine dimethylation of RNA polymerase II C-terminal domain control termination","volume":"529","author":"Zhao","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201757_bib13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1083\/jcb.200304128","article-title":"Smn, the spinal muscular atrophy\u2013determining gene product, modulates axon growth and localization of \u03b2-actin mRNA in growth cones of motoneurons","volume":"163","author":"Rossoll","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omta.2026.201757_bib14","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1093\/hmg\/ddv428","article-title":"alpha-COP binding to the survival motor neuron protein SMN is required for neuronal process outgrowth","volume":"24","author":"Li","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2026.201757_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051826","article-title":"The spinal muscular atrophy disease protein SMN is linked to the Golgi network","volume":"7","author":"Ting","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201757_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000921","article-title":"Ribonucleoprotein Assembly Defects Correlate with Spinal Muscular Atrophy Severity and Preferentially Affect a Subset of Spliceosomal snRNPs","volume":"2","author":"Gabanella","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201757_bib17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2008.03.031","article-title":"SMN Deficiency Causes Tissue-Specific Perturbations in the Repertoire of snRNAs and Widespread Defects in Splicing","volume":"133","author":"Zhang","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201757_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mcn.2009.05.009","article-title":"SMN, profilin IIa and plastin 3: a link between the deregulation of actin dynamics and SMA pathogenesis","volume":"42","author":"Bowerman","year":"2009","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.omta.2026.201757_bib19","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddq021","article-title":"Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model","volume":"19","author":"Bowerman","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2026.201757_bib20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense Masking of an hnRNP A1\/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omta.2026.201757_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201757_bib22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201757_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13123418","article-title":"Patients' Perceptions of Nusinersen Effects According to Their Responder Status","volume":"13","author":"Lilien","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omta.2026.201757_bib24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41591-025-04193-6","article-title":"High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial","volume":"32","author":"Finkel","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201757_bib25","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene Abeparvovec: First Global Approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.omta.2026.201757_bib26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201757_bib27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib28","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib29","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210268","article-title":"Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy: The Phase 3b SMART Study","volume":"104","author":"McMillan","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.omta.2026.201757_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1474-4422(23)00419-2","article-title":"Challenges and opportunities in spinal muscular atrophy therapeutics","volume":"23","author":"Yeo","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib31","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/acn3.51889","article-title":"Combination disease-modifying treatment in spinal muscular atrophy: A proposed classification","volume":"10","author":"Proud","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib32","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.2147\/IJGM.S369021","article-title":"Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy","volume":"15","author":"Ramos-Platt","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.omta.2026.201757_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061764","article-title":"Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy","volume":"15","author":"Ren\u00e9","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omta.2026.201757_bib34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omta.2026.201757_bib35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41591-025-04119-2","article-title":"Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial","volume":"32","author":"Kwon","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201757_bib36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-025-04103-w","article-title":"Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial","volume":"32","author":"Proud","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201757_bib37","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.omta.2026.201757_bib38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bcp.13786","article-title":"A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier","volume":"85","author":"Sturm","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.omta.2026.201757_bib39","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in Type 1 Spinal Muscular Atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201757_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201757_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/11772719211035643","article-title":"Update on Biomarkers in Spinal Muscular Atrophy","volume":"16","author":"Pino","year":"2021","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.omta.2026.201757_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139950","article-title":"Biomarker for Spinal Muscular Atrophy: Expression of SMN in Peripheral Blood of SMA Patients and Healthy Controls","volume":"10","author":"Czech","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201757_bib43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-510X(99)00325-1","article-title":"Analysis of the mRNA transcripts of the survival motor neuron (SMN) gene in the tissue of an SMA fetus and the peripheral blood mononuclear cells of normals, carriers and SMA patients","volume":"173","author":"Jong","year":"2000","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.omta.2026.201757_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050763","article-title":"Evaluation of Peripheral Blood Mononuclear Cell Processing and Analysis for Survival Motor Neuron Protein","volume":"7","author":"Kobayashi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201757_bib45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acn3.283","article-title":"Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study","volume":"3","author":"Kolb","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167087","article-title":"A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls","volume":"11","author":"Wadman","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201757_bib47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmedgenet-2018-105482","article-title":"Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol","volume":"56","author":"Tiziano","year":"2019","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.omta.2026.201757_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035462","article-title":"Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study","volume":"7","author":"Finkel","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201757_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060113","article-title":"SMA-MAP: a plasma protein panel for spinal muscular atrophy","volume":"8","author":"Kobayashi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201757_bib50","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3233\/JND-230054","article-title":"Identifying Biomarkers of Spinal Muscular Atrophy for Further Development","volume":"10","author":"Glascock","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omta.2026.201757_bib51","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419846058","article-title":"Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment","volume":"12","author":"Wurster","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.omta.2026.201757_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16393","article-title":"Neurofilament light chain and profilin-1 dynamics in 30 spinal muscular atrophy type 3 patients treated with nusinersen","volume":"31","author":"Musso","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib54","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12035-019-01698-3","article-title":"Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders","volume":"57","author":"Alirezaei","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.omta.2026.201757_bib55","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jnc.14953","article-title":"Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy","volume":"153","author":"Kessler","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.omta.2026.201757_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12206696","article-title":"Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy","volume":"12","author":"Beaudin","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omta.2026.201757_bib57","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/ene.15331","article-title":"Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy","volume":"29","author":"Schorling","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib58","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1007\/s00415-024-12670-0","article-title":"Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy","volume":"271","author":"Dobelmann","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib59","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00415-025-12909-4","article-title":"Multi-omics profiling in spinal muscular atrophy (SMA): investigating lipid and metabolic alterations through longitudinal CSF analysis of Nusinersen-treated patients","volume":"272","author":"Zandl-Lang","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib60","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41434-025-00513-0","article-title":"Identifying novel response markers for spinal muscular atrophy revealed by targeted proteomics following gene therapy","volume":"33","author":"Pant","year":"2026","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201757_bib61","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00018-024-05426-6","article-title":"Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy","volume":"81","author":"Panicucci","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omta.2026.201757_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14313-z","article-title":"Survival Motor Neuron Protein is Released from Cells in Exosomes: A Potential Biomarker for Spinal Muscular Atrophy","volume":"7","author":"Nash","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201757_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202000301","article-title":"Label-free quantitative proteomic analysis of extracellular vesicles released from fibroblasts derived from patients with spinal muscular atrophy","volume":"21","author":"Roberto","year":"2021","journal-title":"Proteomics"},{"key":"10.1016\/j.omta.2026.201757_bib64","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v4.27066","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Y\u00e1\u00f1ez-M\u00f3","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.omta.2026.201757_bib65","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s13365-018-0695-4","article-title":"Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease","volume":"25","author":"Pulliam","year":"2019","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.omta.2026.201757_bib66","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41398-019-0459-9","article-title":"The emerging role of exosomes in mental disorders","volume":"9","author":"Saeedi","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.omta.2026.201757_bib67","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.2174\/1381612825666191014164950","article-title":"Extracellular Vesicles as Therapeutics for Brain Injury and Disease","volume":"25","author":"Upadhya","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.omta.2026.201757_bib68","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2017.07.001","article-title":"Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases","volume":"262","author":"Rufino-Ramos","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omta.2026.201757_bib69","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.18632\/oncotarget.13635","article-title":"DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients","volume":"8","author":"Garc\u00eda-Romero","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omta.2026.201757_bib70","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ncb1800","article-title":"Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers","volume":"10","author":"Skog","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omta.2026.201757_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040492","article-title":"Delivery of Therapeutic Agents to the Central Nervous System and the Promise of Extracellular Vesicles","volume":"13","author":"Ren\u00e9","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omta.2026.201757_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.vesic.2023.100030","article-title":"Exomap1 mouse: a transgenic model for in vivo studies of exosome biology","volume":"2","author":"Fordjour","year":"2023","journal-title":"Extracell. Vesicle"},{"key":"10.1016\/j.omta.2026.201757_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101259","article-title":"Bioengineering extracellular vesicle cargo for optimal therapeutic efficiency","volume":"32","author":"Ren\u00e9","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201757_bib74","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1038\/s41598-025-90083-3","article-title":"Extracellular vesicles efficiently deliver survival motor neuron protein to cells in culture","volume":"15","author":"Ren\u00e9","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201757_bib75","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s00018-011-0689-3","article-title":"Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles","volume":"68","author":"Gy\u00f6rgy","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omta.2026.201757_bib76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.neurobiolaging.2018.10.006","article-title":"Extracellular vesicles, new actors in the search for biomarkers of dementias","volume":"74","author":"G\u00e1mez-Valero","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.omta.2026.201757_bib77","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/21678421.2014.905606","article-title":"Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases","volume":"15","author":"Feneberg","year":"2014","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"10.1016\/j.omta.2026.201757_bib78","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","article-title":"Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study","volume":"11","author":"Fiandaca","year":"2015","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.omta.2026.201757_bib79","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acn3.175","article-title":"Identification of distinct circulating exosomes in Parkinson's disease","volume":"2","author":"Tomlinson","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib80","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","article-title":"Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial","volume":"76","author":"Athauda","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib81","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1097\/QAD.0000000000001595","article-title":"Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV","volume":"31","author":"Sun","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.omta.2026.201757_bib82","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/02699052.2018.1471738","article-title":"Higher exosomal tau, amyloid-beta 42 and IL-10 are associated with mild TBIs and chronic symptoms in military personnel","volume":"32","author":"Gill","year":"2018","journal-title":"Brain Inj."},{"key":"10.1016\/j.omta.2026.201757_bib83","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients","volume":"17","author":"O'Hagen","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201757_bib84","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1177\/0883073811420294","article-title":"Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III","volume":"26","author":"Glanzman","year":"2011","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib85","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.omta.2026.201757_bib86","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbcan.2018.11.006","article-title":"What is the blood concentration of extracellular vesicles? Implications for the use of extracellular vesicles as blood-borne biomarkers of cancer","volume":"1871","author":"Johnsen","year":"2019","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.omta.2026.201757_bib87","doi-asserted-by":"crossref","first-page":"447","DOI":"10.20517\/evcna.2023.14","article-title":"Advances in extracellular vesicle isolation methods: a path towards cell-type specific EV isolation","volume":"4","author":"Shami-Shah","year":"2023","journal-title":"Extracell. Vesicles Circ. Nucl. Acids"},{"key":"10.1016\/j.omta.2026.201757_bib88","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Th\u00e9ry","year":"2018","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.omta.2026.201757_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.omta.2026.201757_bib90","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.nmd.2016.06.459","article-title":"Opening the window: the care for carrier and perinatal screening for spinal muscular atrophy","volume":"26","author":"Burns","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201757_bib91","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41591-022-01889-x","article-title":"Early treatment is a lifeline for infants with SMA","volume":"28","author":"Sumner","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201757_bib92","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201757_bib93","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201757_bib94","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1007\/s12325-025-03260-1","article-title":"Systematic Review and Meta-analysis of Long-Term Nusinersen Effectiveness in Adolescents and Adults with Spinal Muscular Atrophy","volume":"42","author":"Hagenacker","year":"2025","journal-title":"Adv. Ther."},{"key":"10.1016\/j.omta.2026.201757_bib95","article-title":"Assessment of safety and efficacy of risdiplam treatment in adults with spinal muscular atrophy","volume":"16","author":"Jaworek","year":"2025","journal-title":"Front. Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib96","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/acn3.50855","article-title":"Abnormal fatty acid metabolism is a core component of spinal muscular atrophy","volume":"6","author":"Deguise","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omta.2026.201757_bib97","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ab.2012.06.004","article-title":"Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients","volume":"428","author":"Gercel-Taylor","year":"2012","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.omta.2026.201757_bib98","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.2337\/db17-1308","article-title":"Altered Extracellular Vesicle Concentration, Cargo, and Function in Diabetes","volume":"67","author":"Freeman","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.omta.2026.201757_bib99","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/CIRCRESAHA.113.300858","article-title":"Microvesicles as cell-cell messengers in cardiovascular diseases","volume":"114","author":"Loyer","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.omta.2026.201757_bib100","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12916-024-03475-z","article-title":"Circulating small extracellular vesicles in Alzheimer's disease: a case-control study of neuro-inflammation and synaptic dysfunction","volume":"22","author":"Singh","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.omta.2026.201757_bib101","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1161\/CIRCRESAHA.117.309417","article-title":"Methodological Guidelines to Study Extracellular Vesicles","volume":"120","author":"Coumans","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.omta.2026.201757_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12400","article-title":"A beginner's guide to study extracellular vesicles in human blood plasma and serum","volume":"13","author":"Nieuwland","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.omta.2026.201757_bib103","doi-asserted-by":"crossref","first-page":"e2332","DOI":"10.1212\/WNL.0000000000011853","article-title":"Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying alpha-Synuclein-Containing Extracellular Vesicles","volume":"96","author":"Hong","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.omta.2026.201757_bib104","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/neu.2017.5515","article-title":"Severe Traumatic Brain Injury Induces Early Changes in the Physical Properties and Protein Composition of Intracranial Extracellular Vesicles","volume":"36","author":"Kuhari\u0107","year":"2019","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.omta.2026.201757_bib105","article-title":"Nanoparticles in 472 Human Cerebrospinal Fluid: Changes in Extracellular Vesicle Concentration and miR-21 Expression as a Biomarker for Leptomeningeal Metastasis","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omta.2026.201757_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113116","article-title":"Cerebrospinal fluid extracellular vesicles undergo age dependent declines and contain known and novel non-coding RNAs","volume":"9","author":"Tietje","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201757_bib107","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/s41598-017-01386-z","article-title":"Age-Related Changes in Plasma Extracellular Vesicle Characteristics and Internalization by Leukocytes","volume":"7","author":"Eitan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201757_bib108","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/0006-291X(90)91601-N","article-title":"Characterization of soluble vs membrane-bound human placental 5'-nucleotidase","volume":"172","author":"Klemens","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omta.2026.201757_bib109","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11302-018-9628-1","article-title":"Multiple steps determine CD73 shedding from RPE: lipid raft localization, ARA1 interaction, and MMP-9 up-regulation","volume":"14","author":"Zhang","year":"2018","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.omta.2026.201757_bib110","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.tim.2025.01.009","article-title":"ESCRTs - a multi-purpose membrane remodeling device encoded in all life forms","volume":"33","author":"Nachmias","year":"2025","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.omta.2026.201757_bib111","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/19768354.2024.2380294","article-title":"ESCRT-III: a versatile membrane remodeling machinery and its implications in cellular processes and diseases","volume":"28","author":"Park","year":"2024","journal-title":"Anim. Cells Syst."},{"key":"10.1016\/j.omta.2026.201757_bib112","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0092-8674(01)00434-2","article-title":"Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I","volume":"106","author":"Katzmann","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201757_bib113","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1534-5807(02)00220-4","article-title":"Escrt-III: an endosome-associated heterooligomeric protein complex required for mvb sorting","volume":"3","author":"Babst","year":"2002","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omta.2026.201757_bib114","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nature07836","article-title":"Membrane scission by the ESCRT-III complex","volume":"458","author":"Wollert","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201757_bib115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41580-019-0177-4","article-title":"The many functions of ESCRTs","volume":"21","author":"Vietri","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omta.2026.201757_bib116","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1038\/s41467-019-12507-9","article-title":"The midbody interactome reveals unexpected roles for PP1 phosphatases in cytokinesis","volume":"10","author":"Capalbo","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201757_bib117","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/hmg\/ddm309","article-title":"CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro","volume":"17","author":"van der Zee","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2026.201757_bib118","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1212\/01.wnl.0000231510.89311.8b","article-title":"ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B)","volume":"67","author":"Parkinson","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.omta.2026.201757_bib119","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/jnnp.69.2.150","article-title":"Hereditary spastic paraparesis: a review of new developments","volume":"69","author":"McDermott","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.omta.2026.201757_bib120","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/hmg\/ddv633","article-title":"alpha-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease","volume":"25","author":"Spencer","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2026.201757_bib121","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cell.2011.02.039","article-title":"Loss of skywalker reveals synaptic endosomes as sorting stations for synaptic vesicle proteins","volume":"145","author":"Uytterhoeven","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201757_bib122","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005290","article-title":"Motor and Sensory Deficits in the teetering Mice Result from Mutation of the ESCRT Component HGS","volume":"11","author":"Watson","year":"2015","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omta.2026.201757_bib123","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.semcdb.2017.08.013","article-title":"The role of ESCRT during development and functioning of the nervous system","volume":"74","author":"Sadoul","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.omta.2026.201757_bib124","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","article-title":"Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice","volume":"29","author":"Kong","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.omta.2026.201757_bib125","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.2174\/15665240113139990044","article-title":"At the \u201cjunction\u201d of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression","volume":"13","author":"Goulet","year":"2013","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.omta.2026.201757_bib126","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1021\/acs.jproteome.9b00503","article-title":"Mass Spectrometry-Based Plasma Proteomics: Considerations from Sample Collection to Achieving Translational Data","volume":"18","author":"Ignjatovic","year":"2019","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.omta.2026.201757_bib127","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"Gold","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201757_bib128","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1021\/acs.jproteome.4c00667","article-title":"Variability of 7K and 11K SomaScan Plasma Proteomics Assays","volume":"23","author":"Candia","year":"2024","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.omta.2026.201757_bib129","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22116-0","article-title":"Assessment of variability in the plasma 7k SomaScan proteomics assay","volume":"12","author":"Candia","year":"2022","journal-title":"Sci. Rep."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:12:19Z","timestamp":1788556339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26000923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":129,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3117387X26000923"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201757","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extracellular vesicles as biomarkers of disease progression and therapeutic response in patients with spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201757"}}